Repligen (RGEN) Keeps "Overweight" Rating, Adjusts Price Target to $175.00

Wells Fargo analyst Brandon Couillard maintains an "Overweight" rating for Repligen (RGEN) with an adjusted price target of $175.00, a 2.78% decrease from $180.00. The average target price for RGEN is $179.46, with a high estimate of $220.00 and a low estimate of $130.00, implying a 44.08% upside from the current price of $124.56. The average brokerage recommendation is 2.0, indicating an "Outperform" status. The estimated GF Value for RGEN in one year is $178.65, suggesting a 43.43% upside from the current price.

Wells Fargo analyst Brandon Couillard has maintained an "Overweight" rating for Repligen (RGEN) while adjusting the price target to $175.00. This represents a 2.78% decrease from the previous target of $180.00 [1]. Despite the downward revision, the analyst's confidence in Repligen's market performance potential remains intact.

The updated price target aligns with the average target price for RGEN, which stands at $179.46. The high estimate for the stock is $220.00, while the low estimate is $130.00, indicating a potential upside of 44.08% from the current price of $124.56 [1]. The consensus brokerage recommendation for RGEN is 2.0, indicating an "Outperform" status [1].

GuruFocus estimates the GF Value for RGEN in one year to be $178.65, suggesting a 43.43% upside from the current price of $124.555 [1]. This value is calculated based on historical multiples and future performance estimates, providing a fair value benchmark for the stock.

Investors are encouraged to consider these updated figures when evaluating their investment strategies in Repligen. The stock remains a focus for investors, with a cautious yet optimistic outlook from Wells Fargo aligning with the latest financial insights and market trends.

References:
[1] https://www.gurufocus.com/news/3017568/repligen-rgen-maintains-overweight-rating-with-adjusted-price-target-rgen-stock-news